BRPI0920635A2 - Sais de acido isobutirico (1r*,2r*,4r*)-2-(2-{[3-(4,7- dimetoxi-1h-benzoimidazol-2-il)-propil]-metil}-etil)-5- fenil-biciclo [2.2.2] oct-5-en-2-ila - Google Patents

Sais de acido isobutirico (1r*,2r*,4r*)-2-(2-{[3-(4,7- dimetoxi-1h-benzoimidazol-2-il)-propil]-metil}-etil)-5- fenil-biciclo [2.2.2] oct-5-en-2-ila

Info

Publication number
BRPI0920635A2
BRPI0920635A2 BRPI0920635A BRPI0920635A BRPI0920635A2 BR PI0920635 A2 BRPI0920635 A2 BR PI0920635A2 BR PI0920635 A BRPI0920635 A BR PI0920635A BR PI0920635 A BRPI0920635 A BR PI0920635A BR PI0920635 A2 BRPI0920635 A2 BR PI0920635A2
Authority
BR
Brazil
Prior art keywords
biciclo
dimetoxi
methil
propil
fenil
Prior art date
Application number
BRPI0920635A
Other languages
English (en)
Inventor
Renneberg Dorte
Hubler Francis
Funel Jacques-Alexis
Reichenbaecher Katharina
Hilpert Kurt
Von Raumer Markus
Abele Stefan
Combes Stephanie
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41403088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920635(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0920635A2 publication Critical patent/BRPI0920635A2/pt
Publication of BRPI0920635B1 publication Critical patent/BRPI0920635B1/pt
Publication of BRPI0920635B8 publication Critical patent/BRPI0920635B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0920635A 2008-10-22 2009-10-21 sais do éster do ácido (1r*,2r*,4r*)-2-(2-{[3-(4,7-dimetoxi-1h-benzoilimidazol-2-il)-propil]-metil-amino}-etil)-5-fenil-biciclo[2.2.2]oct-5-en-2-il isobutírico, uso do mesmo, e, composição farmacêutica BRPI0920635B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2008054351 2008-10-22
IBPCTIB2008054351 2008-10-22
PCT/IB2009/054637 WO2010046857A1 (en) 2008-10-22 2009-10-21 Salts of isobutyric acid (1 r*, 2r*, 4r* ) -2- (2-{ [3- (4, 7-dimeth0xy-1 h-benzoimidazol-2-yl) -propyl] -methyl-amino } -ethyl) -5-phenyl-bicyclo [2.2.2] oct-5- en- 2 -yl

Publications (3)

Publication Number Publication Date
BRPI0920635A2 true BRPI0920635A2 (pt) 2018-03-13
BRPI0920635B1 BRPI0920635B1 (pt) 2021-02-23
BRPI0920635B8 BRPI0920635B8 (pt) 2021-05-25

Family

ID=41403088

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920635A BRPI0920635B8 (pt) 2008-10-22 2009-10-21 sais do éster do ácido (1r*,2r*,4r*)-2-(2-{[3-(4,7-dimetoxi-1h-benzoilimidazol-2-il)-propil]-metil-amino}-etil)-5-fenil-biciclo[2.2.2]oct-5-en-2-il isobutírico, uso do mesmo, e, composição farmacêutica

Country Status (22)

Country Link
US (1) US8492555B2 (pt)
EP (1) EP2344461B1 (pt)
JP (1) JP4913926B2 (pt)
KR (1) KR101331291B1 (pt)
CN (1) CN102186828B (pt)
AR (1) AR074049A1 (pt)
AU (1) AU2009306002B2 (pt)
BR (1) BRPI0920635B8 (pt)
CA (1) CA2740722C (pt)
CL (1) CL2011000921A1 (pt)
DK (1) DK2344461T3 (pt)
ES (1) ES2618178T3 (pt)
HU (1) HUE032044T2 (pt)
IL (1) IL212405A (pt)
MA (1) MA32817B1 (pt)
MX (1) MX342043B (pt)
MY (1) MY160597A (pt)
NZ (1) NZ592996A (pt)
RU (1) RU2516247C2 (pt)
TW (1) TWI463981B (pt)
WO (1) WO2010046857A1 (pt)
ZA (1) ZA201103734B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0920635B8 (pt) 2008-10-22 2021-05-25 Actelion Pharmaceuticals Ltd sais do éster do ácido (1r*,2r*,4r*)-2-(2-{[3-(4,7-dimetoxi-1h-benzoilimidazol-2-il)-propil]-metil-amino}-etil)-5-fenil-biciclo[2.2.2]oct-5-en-2-il isobutírico, uso do mesmo, e, composição farmacêutica
KR101836552B1 (ko) * 2010-10-20 2018-03-08 아이도시아 파마수티컬즈 리미티드 바이시클로[2.2.2]옥탄-2-온 화합물의 부분입체선택적 제조

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
WO2003031415A1 (en) * 2001-10-10 2003-04-17 Aryx Therapeutics Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
JP4595040B2 (ja) * 2007-04-27 2010-12-08 アクテリオン ファーマシューティカルズ リミテッド 架橋６員環化合物
KR101364909B1 (ko) * 2008-04-25 2014-02-21 액테리온 파마슈티칼 리미티드 칼슘 채널 차단제로서의 벤지미다졸 유도체
BRPI0920635B8 (pt) 2008-10-22 2021-05-25 Actelion Pharmaceuticals Ltd sais do éster do ácido (1r*,2r*,4r*)-2-(2-{[3-(4,7-dimetoxi-1h-benzoilimidazol-2-il)-propil]-metil-amino}-etil)-5-fenil-biciclo[2.2.2]oct-5-en-2-il isobutírico, uso do mesmo, e, composição farmacêutica
US8314253B2 (en) 2008-10-22 2012-11-20 Actelion Pharmaceuticals Ltd. Bridged tetrahydronaphthalene derivatives
WO2010046729A2 (en) 2008-10-23 2010-04-29 Actelion Pharmaceuticals Ltd Tetrahydronaphthalene compounds

Also Published As

Publication number Publication date
CN102186828B (zh) 2014-07-16
EP2344461A1 (en) 2011-07-20
ZA201103734B (en) 2015-12-23
CN102186828A (zh) 2011-09-14
HUE032044T2 (en) 2017-08-28
US8492555B2 (en) 2013-07-23
BRPI0920635B1 (pt) 2021-02-23
TWI463981B (zh) 2014-12-11
CA2740722A1 (en) 2010-04-29
RU2516247C2 (ru) 2014-05-20
AU2009306002A1 (en) 2010-04-29
JP4913926B2 (ja) 2012-04-11
EP2344461B1 (en) 2016-12-14
JP2012506416A (ja) 2012-03-15
CA2740722C (en) 2017-08-22
WO2010046857A1 (en) 2010-04-29
IL212405A (en) 2016-05-31
CL2011000921A1 (es) 2011-11-11
US20110263667A1 (en) 2011-10-27
IL212405A0 (en) 2011-06-30
KR101331291B1 (ko) 2013-11-22
NZ592996A (en) 2013-01-25
DK2344461T3 (en) 2017-02-13
KR20110075030A (ko) 2011-07-05
TW201021796A (en) 2010-06-16
AU2009306002B2 (en) 2015-01-15
AR074049A1 (es) 2010-12-22
RU2011120042A (ru) 2012-11-27
MA32817B1 (fr) 2011-11-01
MX2011004138A (es) 2011-07-20
BRPI0920635B8 (pt) 2021-05-25
MY160597A (en) 2017-03-15
ES2618178T3 (es) 2017-06-21
MX342043B (es) 2016-09-12

Similar Documents

Publication Publication Date Title
HUS2000040I1 (hu) Fungicid szubsztituált 2-[2.halogénalkil-4-(fenoxi-fenil]-1-[1,2,4]triazol-1-il-etanol vegyületek
PL2342837T3 (pl) Asymetryczny protokół sterowania wiązką
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
DK3309139T3 (da) Process for the preparation of 2,3,3,3-trifluoropropene
BRPI0910734A2 (pt) composto, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo.
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
HRP20130606T1 (en) Composition having biocide activity for aqueous preparations
PT3112358T (pt) Sais de xantílio 3,6-dissubstituídos
BRPI0918637A2 (pt) composição antimicrobiana.
ZA201103259B (en) Live,attentuated respiratory syncytial virus
BRPI0912762A2 (pt) parte de distribuidor.
BRPI0912761A2 (pt) parte de distribuidor.
FR2932490B1 (fr) Composition polyamide.
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
BR112012012449A2 (pt) "processo para preparar 2-isoxazolinas 5,5-dissubstituídas"
IT1391108B1 (it) Processo per la preparazione di etilidennorbornene.
HRP20181437T1 (hr) Postupak proizvodnje (3s,3s') 4,4' disulfanedilbis (3-aminobutan-1-sulfonske kiseline)
IT1397968B1 (it) Composizione pesticida acquosa.
FR2927900B1 (fr) Procede de preparation d'alpha-aminoacetals optiquement actifs.
FR2929947B1 (fr) Procede de preparation d'une composition photoreticulable.
EP2648522A4 (en) PROTEIN-STABILIZED ANTIMICROBIAL COMPOSITION MOLDED BY MELTING PROCESSING
DK2259683T3 (da) Koncentreret cypermethrin-sammensætning
ITRM20080037A1 (it) Procedimento per la ultrapurificazione di alginati.
BR112012004523A2 (pt) processo para a preparação de (1s,4r)-2-oxa-3-azabiciclo[2.2.1]hept-5-enos
BRPI1011720A2 (pt) compostos de 1,1,1- tri-flúor-2 hidróxi-propila.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2797 DE 13-08-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.